Ornithine ( DrugBank: Ornithine )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
245プロピオン酸血症2
251尿素サイクル異常症34

245. プロピオン酸血症


臨床試験数 : 13 薬物数 : 16 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 6
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01599286
(ClinicalTrials.gov)
September 201211/5/2012Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute HyperammonemiaShort-Term Outcome of N-Carbamylglutamate in the Treatment of Acute HyperammonemiaPropionic Acidemia, Type I and/or Type II;Methylmalonic Acidemia;Carbamoyl-Phosphate Synthase I Deficiency Disease;Ornithine Carbamoyltransferase DeficiencyDrug: Carbaglu;Drug: Placebo;Drug: Standard of Care TreatmentMendel TuchmanChildren's National Research Institute;Boston Children's Hospital;University Hospitals Cleveland Medical Center;University of California, Los Angeles;Children's Hospital of Philadelphia;Stanford University;Icahn School of Medicine at Mount Sinai;University of Pittsburgh;Children's Hospital ColoradoActive, not recruitingN/A99 YearsAll114Phase 2United States
2NCT00645879
(ClinicalTrials.gov)
July 200825/3/2008Anaplerotic Therapy in Propionic AcidemiaSafety & Efficacy of Investigational Products: Ornithine Alpha-ketoglutarate, Glutamine, or Disodium Citrate on Hyperammonemia in Propionic Acidemia.Propionic AcidemiaDrug: ornithine alpha ketoglutarate;Drug: glutamine;Drug: disodium citrateNicola LongoNational Institutes of Health (NIH);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed5 Years12 YearsBoth3Phase 1United States

251. 尿素サイクル異常症


臨床試験数 : 54 薬物数 : 61 - (DrugBank : 15) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 28
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-003384-25-FR
(EUCTR)
16/12/202226/11/2021A clinical study of a virus transferring the gene for human Ornithine Transcarbamylase (OTC) in patients older than 12 years old with late-onset OTC deficiencyA Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Adeno-Associated Virus Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Patients with Late-Onset OTC Deficiency Late-onset Ornithine transcarbamylase (OTC) deficiency
MedDRA version: 20.0;Level: LLT;Classification code 10071107;Term: Ornithine transcarbamylase deficiency;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: DTX301
INN or Proposed INN: avalotcagene ontaparvovec
Product Name: (1-13C) Sodium Acetate
INN or Proposed INN: Sodium Ethanoate (1- 13 C)
Other descriptive name: Sodium acetate (1-13C)
Ultragenyx Pharmaceutical Inc.NULLNot RecruitingFemale: yes
Male: yes
50Phase 3United States;Portugal;Spain;Italy;United Kingdom;France;Canada;Argentina;Brazil;Croatia;Australia;Germany;Netherlands;Japan
2NCT05345171
(ClinicalTrials.gov)
October 18, 202218/4/2022Clinical Study of DTX301 AAV- Mediated Gene Transfer for Ornithine Transcarbamylase(OTC) DeficiencyA Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adeno-associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Patients With Late-onset OTC DeficiencyOTC DeficiencyGenetic: DTX301;Other: Placebo;Drug: Oral Corticosteroids;Drug: Placebo for oral corticosteroids;Drug: Sodium AcetateUltragenyx Pharmaceutical IncNULLRecruiting12 YearsN/AAll50Phase 3United States;Argentina;Australia;Brazil;Canada;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom
3EUCTR2020-003384-25-DE
(EUCTR)
02/08/202217/12/2021A clinical study of a virus transferring the gene for human Ornithine Transcarbamylase (OTC) in patients older than 12 years old with late-onset OTC deficiencyA Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Adeno-Associated Virus Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Patients with Late-Onset OTC Deficiency Late-onset Ornithine transcarbamylase (OTC) deficiency
MedDRA version: 20.0;Level: LLT;Classification code 10071107;Term: Ornithine transcarbamylase deficiency;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: DTX301
INN or Proposed INN: avalotcagene ontaparvovec
Product Name: (1-13C) Sodium Acetate
INN or Proposed INN: Sodium Ethanoate (1- 13 C)
Other descriptive name: Sodium acetate (1-13C)
Ultragenyx Pharmaceutical Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 3United States;Portugal;Spain;United Kingdom;Italy;France;Canada;Argentina;Brazil;Croatia;Australia;Germany;Netherlands;Japan
4NCT05526066
(ClinicalTrials.gov)
July 6, 20228/8/2022Study for Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency;OTC Deficiency;OTCDBiological: ARCT-810;Other: PlaceboArcturus Therapeutics, Inc.NULLRecruiting12 Years65 YearsAll24Phase 2Belgium;Spain;United Kingdom
5EUCTR2020-003384-25-ES
(EUCTR)
04/04/202217/12/2021A clinical study of a virus transferring the gene for human Ornithine Transcarbamylase (OTC) in patients older than 12 years old with late-onset OTC deficiencyA Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Adeno-Associated Virus Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Patients with Late-Onset OTC Deficiency Late-onset Ornithine transcarbamylase (OTC) deficiency
MedDRA version: 20.0;Level: LLT;Classification code 10071107;Term: Ornithine transcarbamylase deficiency;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: DTX301
INN or Proposed INN: avalotcagene ontaparvovec
Product Name: (1-13C) Sodium Acetate
INN or Proposed INN: Sodium Ethanoate (1-13C)
Other descriptive name: Sodium acetate (1-13C)
Ultragenyx Pharmaceutical Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 3Portugal;United States;Spain;Italy;United Kingdom;France;Canada;Argentina;Brazil;Croatia;Australia;Germany;Netherlands;Japan
6NCT05092685
(ClinicalTrials.gov)
February 1, 202228/9/2021Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEnPhase I/II Open Label, Multicentre Clinical Trial to Assess Safety and Efficacy of AAVLK03hOTC for Paediatric Patients With Ornithine Transcarbamylase Deficiency.Ornithine Transcarbamylase DeficiencyGenetic: AAVLK03hOTCUniversity College, LondonNULLNot yet recruitingN/A16 YearsAll12Phase 1/Phase 2NULL
7EUCTR2021-001081-38-ES
(EUCTR)
12/01/202231/08/2021A Multi-dose Study of an Investigational Treatment to Evaluate Safety, Tolerability, and Ability to Improve Urea Cycle Function in Adolescents and Adults with Ornithine Transcarbamylase DeficiencyPhase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants with Ornithine Transcarbamylase Deficiency - Phase 2 nested single/multiple ascending dose study of ARCT-810 in Participants with OTC Deficiency Ornithine transcarbamylase deficiency
MedDRA version: 21.1;Level: LLT;Classification code 10013373;Term: Disorders of urea cycle metabolism;System Organ Class: 200000003094;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: ARCT-810
Product Code: ARCT-810
INN or Proposed INN: Not assigned
Other descriptive name: mRNA encoding modified Ornithine transcarbamylase
Arcturus Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
24Phase 2Belgium;Spain;United Kingdom
8EUCTR2018-000156-18-FR
(EUCTR)
02/11/202031/01/2020A clinical study to learn about the effects of a virus that transfers the gene for human Ornithine Transcarbamylase (OTC) in adults with late-onset OTC deficiency in the long termA Long-Term Follow-up Study to Evaluate the Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OTC Deficiency Ornithine transcarbamylase deficiency
MedDRA version: 20.0;Level: LLT;Classification code 10071107;Term: Ornithine transcarbamylase deficiency;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: DTX301
INN or Proposed INN: Not yet assigned
Other descriptive name: DTX301
Ultragenyx Pharmaceutical, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
18Phase 1;Phase 2United States;France;Canada;Spain;United Kingdom
9NCT03767270
(ClinicalTrials.gov)
December 201928/11/2018Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC DeficiencyA Phase 1/2 Single Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered MRT5201 in Subjects With Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase DeficiencyBiological: MRT5201;Other: PlaceboTranslate Bio, Inc.NULLWithdrawn18 YearsN/AAll0Phase 1/Phase 2NULL
10JPRN-jRCTs041190055
24/07/201924/07/2019Carglumic Acid Administration for OTC DeficienscyA Clinical Study of Carglumic Acid in Patients with Late-Onset Ornithine Transcarbamylase Deficiency ornitine transcarbamylase deficiency patientsadministraton of carglumic acidIto TetsuyaNULLCompleteNot applicable< 75age oldBoth2Phase 4Japan
11EUCTR2018-000156-18-GB
(EUCTR)
15/08/201802/05/2018A clinical study to learn about the effects of a virus that transfers the gene for human Ornithine Transcarbamylase (OTC) in adults with late-onset OTC deficiency in the long termA Long-Term Follow-up Study to Evaluate the Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OTC Deficiency Ornithine transcarbamylase deficiency
MedDRA version: 20.0;Level: LLT;Classification code 10071107;Term: Ornithine transcarbamylase deficiency;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: DTX301
INN or Proposed INN: Not yet assigned
Other descriptive name: DTX301
Ultragenyx Pharmaceutical, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
18Phase 1;Phase 2United States;Canada;Spain;United Kingdom
12EUCTR2018-000156-18-ES
(EUCTR)
18/06/201814/05/2018A clinical study to learn about the effects of a virus that transfers the gene for human Ornithine Transcarbamylase (OTC) in adults with late-onset OTC deficiency in the long termA Long-Term Follow-up Study to Evaluate the Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OTC Deficiency Ornithine transcarbamylase deficiency
MedDRA version: 20.0;Level: LLT;Classification code 10071107;Term: Ornithine transcarbamylase deficiency;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: DTX301
INN or Proposed INN: Not yet assigned
Other descriptive name: DTX301
Ultragenyx Pharmaceutical, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
9Phase 1;Phase 2United States;Canada;Spain;United Kingdom
13NCT02991144
(ClinicalTrials.gov)
July 31, 20179/12/2016Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) DeficiencyA Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC DeficiencyOrnithine Transcarbamylase (OTC) DeficiencyGenetic: scAAV8OTC;Drug: Reactive Corticosteroid Taper Regimen;Drug: Prophylactic Corticosteroid Taper RegimenUltragenyx Pharmaceutical IncNULLCompleted18 YearsN/AAll16Phase 1/Phase 2United States;Canada;Spain;United Kingdom
14EUCTR2016-001057-40-GB
(EUCTR)
14/03/201715/12/2016An early-phase clinical study of a virus transferring the gene for human Ornithine Transcarbamylase (OTC) in adults with late-onset OTC deficiencyA Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OTC Deficiency Ornithine transcarbamylase deficiency
MedDRA version: 20.0;Level: LLT;Classification code 10071107;Term: Ornithine transcarbamylase deficiency;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: DTX301
INN or Proposed INN: Not yet assigned
Other descriptive name: DTX301
Ultragenyx Pharmaceutical, Inc.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
18 Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;Canada;Spain;United Kingdom
15EUCTR2016-001057-40-ES
(EUCTR)
08/03/201727/12/2016An early-phase clinical study of a virus transferring the gene for human Ornithine Transcarbamylase (OTC) in adults with late-onset OTC deficiency.A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OTC Deficiency. Ornithine transcarbamylase deficiency
MedDRA version: 19.0;Level: LLT;Classification code 10071107;Term: Ornithine transcarbamylase deficiency;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: DTX301
INN or Proposed INN: Not yet assigned
Other descriptive name: DTX301
Dimension Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Phase 1;Phase 2France;United States;Canada;Spain;United Kingdom
16NCT02670889
(ClinicalTrials.gov)
November 201614/1/2016Urease Inhibitor Drug Treatment for Urea Cycle DisordersManipulating the Gut Microbiome in Urea Cycle DisordersOrnithine Transcarbamylase Deficiency;Argininosuccinate Synthetase Deficiency (Citrullinemia);Argininosuccinic Acid Lyase Deficiency (Argininosuccinic Aciduria);Carbamyl-Phosphate Synthase I DeficiencyDrug: Acetohydroxamic Acid;Drug: Isotopic Intravenous [13C]-UreaNicholas Ah MewData Management and Coordinating Center (DMCC);Children's Hospital of PhiladelphiaNot yet recruiting18 Years60 YearsBoth16Phase 1/Phase 2NULL
17EUCTR2014-000650-11-PL
(EUCTR)
11/12/201501/10/2015HEP002 is a clinical study designed for paediatric patients with urea cycle disorders (UCD). UCD patients will receive several infusions of HepaStem. The efficacy as well as the safety of the medicinal product will be assessed during the year following infusions.HEP002: A prospective, open label, multi-country, efficacy and safety study of several infusions of HepaStem in Urea Cycle Disorders pediatric patients. - HEP002 The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are five disorders to be investigated: carbamoylphosphate synthetase I deficiency [CPS ID], ornithine transcarbamylase deficiency [OTCD], argininosuccinic acid synthetase deficiency [ASSD], argininosuccinic acid lyase deficiency [ASLD], arginase deficiency [ARGD].
MedDRA version: 19.0;Level: LLT;Classification code 10013373;Term: Disorders of urea cycle metabolism;System Organ Class: 100000004861;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: HepaStem
INN or Proposed INN: Heterologous Human Adult Liver-derived Progenitor Cells
Promethera BiosciencesNULLNot RecruitingFemale: yes
Male: yes
20Phase 2France;Spain;Belgium;Poland
18EUCTR2014-000650-11-ES
(EUCTR)
13/04/201520/10/2014HEP002 is a clinical study designed for paediatric patients with urea cycle disorders (UCD). UCD patients will receive several infusions of HepaStem. The efficacy as well as the safety of the medicinal product will be assessed during the year following infusions.A prospective, open label, multi-country, multicenter, efficacy and safety study of several infusions of Promethera HepaStem in Urea Cycle Disorders pediatric patients The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are eight disorders: N-Acetylglutamate synthase deficiency, Carbamoyl phosphate synthetase I deficiency, Ornithine transcarbamylase deficiency, citrullinemia type I, argininosuccinic aciduria, argininemia, HHH syndrme and citrullinemia type II.Mutations in each of the enzymes have been identified, resulting in failed production of urea, the end product of the urea cycle.
MedDRA version: 18.0;Level: LLT;Classification code 10013373;Term: Disorders of urea cycle metabolism;System Organ Class: 100000004861;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: HepaStem
INN or Proposed INN: Celulas hepatocitos troncales adultas alogenicas de higado expandidas
Promethera BiosciencesNULLNot RecruitingFemale: yes
Male: yes
20Phase 2France;Poland;Belgium;Spain
19EUCTR2014-000650-11-FR
(EUCTR)
18/02/201526/06/2015HEP002 is a clinical study designed for paediatric patients with urea cycle disorders (UCD). UCD patients will receive several infusions of HepaStem. The efficacy as well as the safety of the medicinal product will be assessed during the year following infusions.A prospective, open label, multicenter, efficacy and safety study of several infusions of Promethera HepaStem in Urea Cycle Disorders pediatric patients - HEP002 The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are seven disorders to be investigated: carbamoylphosphate synthetase I deficiency [CPS ID], ornithine transcarbamylase deficiency [OTCD], argininosuccinic acid synthetase deficiency [ASSD], argininosuccinic acid lyase deficiency [ASLD], arginase deficiency [ARGD], N-acetylglutamate synthase deficiency [NAGSD], and citrine deficiency.
MedDRA version: 18.0;Level: LLT;Classification code 10013373;Term: Disorders of urea cycle metabolism;System Organ Class: 100000004861;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: HepaStem
INN or Proposed INN: Heterologous Human Adult Liver-derived Progenitor Cells
Promethera BiosciencesNULLNot RecruitingFemale: yes
Male: yes
20Phase 2France;Poland;Spain;Belgium
20EUCTR2014-000650-11-BE
(EUCTR)
15/09/201401/07/2014HEP002 is a clinical study designed for paediatric patients with urea cycle disorders (UCD). UCD patients will receive several infusions of HepaStem. The efficacy as well as the safety of the medicinal product will be assessed during the year following infusions.A prospective, open label, multicountry, efficacy and safety study of several infusions of HepaStem in Urea Cycle Disorders pediatric patients. - HEP002 The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are seven disorders to be investigated: carbamoylphosphate synthetase I deficiency [CPS ID], ornithine transcarbamylase deficiency [OTCD], argininosuccinic acid synthetase deficiency [ASSD], argininosuccinic acid lyase deficiency [ASLD], arginase deficiency [ARGD], N-acetylglutamate synthase deficiency [NAGSD], and citrine deficiency.
MedDRA version: 18.0;Level: LLT;Classification code 10013373;Term: Disorders of urea cycle metabolism;System Organ Class: 100000004861;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: HepaStem
INN or Proposed INN: Heterologous Human Adult Liver-derived Progenitor Cells
Promethera BiosciencesNULLNot RecruitingFemale: yes
Male: yes
20Phase 2France;Poland;Spain;Belgium
21EUCTR2013-001045-14-GB
(EUCTR)
30/07/201428/04/2014A long-term safety follow-up study of patients having received infusions of HepaStem.SAF 001: A long-term safety follow-up study of patients having received infusions of HepaStem. - SAF001 Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The UCD are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are 8 disorders: N-Acetylglutamate synthase deficiency, Carbamoyl phosphate synthetase I deficiency, Ornithine transcarbamylase deficiency, citrullinemia I&II, argininosuccinic aciduria, HHH syndrome & argininemia
MedDRA version: 19.0;Level: LLT;Classification code 10021601;Term: Inborn error of metabolism NOS;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: HepaStem
INN or Proposed INN: Heterologous Human Adult Liver-derived Progenitor Cells
Other descriptive name: NA
Promethera BiosciencesNULLNot Recruiting Female: yes
Male: yes
19 Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noPortugal;Belgium;Italy;United Kingdom
22EUCTR2013-001045-14-PT
(EUCTR)
04/04/201402/10/2013A clinical study for evaluating long-term safety of patients suffering from Urea Cycle disorders (UCD) or Crigler-Najjar Syndrome (CN) having received infusions of HepaStem.SAF 001: A long-term safety follow-up study of patients suffering from Urea Cycle disorders (UCD) or Crigler-Najjar Syndrome (CN) having received infusions of HepaStem. - SAF001 Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The UCD are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are 8 disorders: N-Acetylglutamate synthase deficiency, Carbamoyl phosphate synthetase I deficiency, Ornithine transcarbamylase deficiency, citrullinemia I&II, argininosuccinic aciduria, HHH syndrome & argininemia
MedDRA version: 16.0;Level: LLT;Classification code 10021601;Term: Inborn error of metabolism NOS;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: HepaStem
INN or Proposed INN: Heterologous Human Adult Liver-derived Progenitor Cells
Other descriptive name: NA
Promethera BiosciencesNULLNot RecruitingFemale: yes
Male: yes
21Phase 1;Phase 2Portugal;Belgium;Israel;United Kingdom;Italy
23EUCTR2013-001045-14-IT
(EUCTR)
14/02/201431/12/2013A clinical study for evaluating long-term safety of patients having received infusions of HepaStem.SAF 001: A long-term safety follow-up study of patients having received infusions of HepaStem. - SAF001 Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The UCD are inborn errors of metabolism that affect the transfer of nitrogen into urea. Thereare 8 disorders: N-Acetylglutamate synthase deficiency, Carbamoyl phosphate synthetase I deficiency, Ornithine transcarbamylase deficiency, citrullinemia I&II, argininosuccinic aciduria, HHH syndrome & argininemia
MedDRA version: 16.1;Level: LLT;Classification code 10021601;Term: Inborn error of metabolism NOS;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: HepaStem
INN or Proposed INN: Heterologous Human Adult Liver-derived Progenitor Cells
Other descriptive name: NA
Promethera BiosciencesNULLNot RecruitingFemale: yes
Male: yes
21Phase 1;Phase 2Portugal;Belgium;Israel;United Kingdom;Italy
24EUCTR2013-001045-14-BE
(EUCTR)
22/04/201319/03/2013A clinical study for evaluating long-term safety of patients suffering from Urea Cycle disorders (UCD) or Crigler-Najjar Syndrome (CN) having received infusions of HepaStem.SAF 001: A long-term safety follow-up study of patients suffering from Urea Cycle disorders (UCD) or Crigler-Najjar Syndrome (CN) having received infusions of HepaStem. - SAF001 Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are six disorders: N-Acetylglutamate synthase deficiency, Carbamoyl phosphate synthetase I deficiency, Ornithine transcarbamylase deficiency, citrullinemia, argininosuccinic aciduria and argininemia
MedDRA version: 15.1;Level: LLT;Classification code 10021601;Term: Inborn error of metabolism NOS;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: HepaStem
INN or Proposed INN: Heterologous Human Adult Liver-derived Progenitor Cells
Other descriptive name: NA
Promethera BiosciencesNULLNot RecruitingFemale: yes
Male: yes
18Phase 1;Phase 2Portugal;Belgium;United Kingdom;Italy
25EUCTR2011-004074-28-IT
(EUCTR)
19/12/201214/01/2013A phase I/II trial for evaluating both safety and preliminary efficacy of one cycle of Promethera Hepastem in Urea Cycle Disorders and Crigler-Najjar Syndrome patientsA prospective, open label, multicenter, partially randomized, safety study of one cycle of Promethera HepaStem in Urea Cycle Disorders and Crigler-Najjar Syndrome Patients - HEP 001 Crigle-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucoronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are six desorders: N-Acetylglutamate synthase deficiency, Carbamoyl phosphate synthase I deficiency, Ornithine transcarbamylase deficiency, citrullinemia, argininosuccinic aciduria and argininemia.
MedDRA version: 15.1;Level: LLT;Classification code 10013373;Term: Disorders of urea cycle metabolism;System Organ Class: 100000004861
MedDRA version: 15.1;Level: PT;Classification code 10011386;Term: Crigler-Najjar syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 15.1;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;Classification code 10021601;Term: Inborn error of metabolism NOS;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: Promethera HepaStem
Product Code: HHALPC
INN or Proposed INN: Heterologous Human Adult Liver-derived Progenitor Cells (HHALPC)
PROMETHERA BIOSCIENCESNULLNot RecruitingFemale: yes
Male: yes
18Phase 1/2Belgium;United Kingdom;Italy
26EUCTR2011-004074-28-GB
(EUCTR)
20/07/201228/09/2011A phase I/II trial for evaluating both safety and preliminary efficacy of one cycle of Promethera HepaStem® in Urea Cycle Disorders and Crigler-Najjar Syndrome patientsA prospective, open label, multicenter, randomized, safety and preliminary efficacy study of one cycle of Promethera HepaStem® in Urea Cycle Disorders and Crigler-Najjar Syndrome patients - UKHEP001 Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are six disorders: N-Acetylglutamate synthase deficiency, Carbamoyl phosphate synthetase I deficiency, Ornithine transcarbamylase deficiency, citrullinemia, argininosuccinic aciduria and argininemia
MedDRA version: 17.0;Level: LLT;Classification code 10021601;Term: Inborn error of metabolism NOS;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: HepaStem
INN or Proposed INN: Heterologous Human Adult Liver-derived Progenitor Cells
Other descriptive name: NA
Promethera BiosciencesNULLNot RecruitingFemale: yes
Male: yes
21Phase 1/2Belgium;Italy;United Kingdom
27EUCTR2011-004074-28-BE
(EUCTR)
13/02/201221/02/2012A phase I/II trial for evaluating safety of one cycle of Promethera HepaStem in Urea Cycle Disorders and Crigler-Najjar Syndrome patientsHEP 001: A prospective, open label, multicenter, partially randomized, safety study of one cycle of Promethera HepaStem in Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) paediatric patients. - HEP 001 Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are six disorders: N-Acetylglutamate synthase deficiency, Carbamoyl phosphate synthetase I deficiency, Ornithine transcarbamylase deficiency, citrullinemia, argininosuccinic aciduria and argininemia
MedDRA version: 14.1;Level: LLT;Classification code 10021601;Term: Inborn error of metabolism NOS;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: HepaStem
INN or Proposed INN: Heterologous Human Adult Liver-derived Progenitor Cells
Other descriptive name: NA
Promethera BiosciencesNULLNot RecruitingFemale: yes
Male: yes
21Phase 1/2Belgium;Italy;United Kingdom
28NCT00718627
(ClinicalTrials.gov)
July 200816/7/2008Human Heterologous Liver Cells for Infusion in Children With Urea Cycle DisordersOpen, Prospective, Uncontrolled, Multicentre Study to Evaluate The Safety and Efficacy of Multiple Applications of Liver Cell Suspension Into The Portal Vein in Children With Urea Cycle Disorders (UCDs)Urea Cycle Disorders;Carbamoylphosphate Synthetase I Deficiency;Ornithine Transcarbamylase Deficiency;CitrullinemiaBiological: Human Heterologous Liver CellsCytonet GmbH & Co. KGNULLCompletedN/A5 YearsBoth12Phase 2Germany
29EUCTR2006-000136-27-DE
(EUCTR)
17/03/200804/09/2007Open, Prospective, Uncontrolled, Multicentre Study to Evaluate The Safety and Efficacy of Multiple Applications of Liver Cell Suspension Into The Portal Vein in Children with Urea Cycle Disorders (UCDs)Open, Prospective, Uncontrolled, Multicentre Study to Evaluate The Safety and Efficacy of Multiple Applications of Liver Cell Suspension Into The Portal Vein in Children with Urea Cycle Disorders (UCDs) Neonates and Infants up to 3 months including with prenatally or postnatally confirmed urea cycle disorder with below listed deficiency and children aged > 3 months up to 5 years including with confirmed urea cycle disorder and unstable metabolism with deficiency of either: - Carbamyl-phosphate Synthetase I Deficiency (CPS1D) - Ornithine Transcarbamylase Deficiency (OTCD) - Argininosuccinate Synthetase Deficiency (ASSD/Citrullinaemia)can be included.
MedDRA version: 18.1;Level: PT;Classification code 10052450;Term: Ornithine transcarbamoylase deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 18.1;Classification code 10058298;Term: Argininosuccinate synthetase deficiency;Classification code 10058297;Term: Carbamoyl phosphate synthetase deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: Human heterologous liver cells (for infusion)
Product Code: HHLivC
Cytonet GmbH & Co KGNULLNot RecruitingFemale: yes
Male: yes
Germany
30NCT00004307
(ClinicalTrials.gov)
December 199918/10/1999Study of Treatment and Metabolism in Patients With Urea Cycle DisordersTherapeutic and Metabolic Studies of Urea Cycle Disorders: Part A: Nitrogen Flux and Ureagenesis; Part B (Closed): Phase I Adenovirus Vector-Mediated Gene Therapy for Ornithine Transcarbamylase DeficiencyAmino Acid Metabolism, Inborn ErrorsBehavioral: Protein and calorie controlled diet;Genetic: Ornithine transcarbamylase vectorNational Center for Research Resources (NCRR)Baylor College of MedicineRecruiting6 Months64 YearsBoth66Phase 1United States
31NCT00004498
(ClinicalTrials.gov)
July 199818/10/1999Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseGenetic: Adenoviral Vector-Mediated Gene TransferUniversity of PennsylvaniaNULLTerminated18 Years69 YearsBoth21Phase 1NULL
32NCT00004386
(ClinicalTrials.gov)
October 199518/10/1999Phase I Pilot Study of Liver-Directed Gene Therapy for Partial Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseGenetic: recombinant adenovirus containing the ornithine transcarbamylase geneEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Children's Research InstituteTerminated18 Years65 YearsBothPhase 1NULL
33EUCTR2015-000988-14-Outside-EU/EEA
(EUCTR)
12/10/2016Human Heterologous Liver Cells for Infusion in Children With Urea Cycle DisordersTitle: Open, Prospective, Historic-Controlled, Multicenter Study toEvaluate the Safety and Efficacy of Infusion of Liver Cell Suspension(HHLivC) in Children with Urea Cycle Disorders Neonatal-onset type of the following urea cycle disorders(UCD):ornithine transcarbamylase deficiency (OTCD),carbamoylphosphate synthetase I deficiency (CPS1D), orargininosuccinate synthetase deficiency (ASSD orcitrullinemia);Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Product Name: Heparesc
Product Code: HHLivC
INN or Proposed INN: not available
Other descriptive name: ALLOGENIC HUMAN HETEROLOGOUS LIVER CELLS
PROMETHERA Biosciences S.A./N.V.NULLNAFemale: yes
Male: yes
21Phase 2United States;Canada
34EUCTR2021-001081-38-BE
(EUCTR)
26/08/2021Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants with Ornithine Transcarbamylase DeficiencyPhase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants with Ornithine Transcarbamylase Deficiency - Phase 2 nested single/multiple ascending dose study of ARCT-810 in Participants with OTC Deficiency Ornithine transcarbamylase deficiency
MedDRA version: 21.1;Level: LLT;Classification code 10013373;Term: Disorders of urea cycle metabolism;System Organ Class: 200000003094;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Product Name: ARCT-810
Product Code: ARCT-810
INN or Proposed INN: Not assigned
Other descriptive name: mRNA encoding modified Ornithine transcarbamylase
Arcturus Therapeutics, Inc.NULLNAFemale: yes
Male: yes
24Phase 2Belgium;United Kingdom